Disease Landscape and Forecast Insights

Despite considerable progress in the treatment of HR-positive/HER2-negative metastatic breast cancer, the disease remains incurable. The approval and availability of the CDK4/6 inhibitors (Pfizer…

Because of the lack of disease-modifying agents for CKD, treatment is aimed at minimizing the symptoms and complications arising from progressively diminished kidney function and treating the cause…

The treatment of BRAF mutation-positive unresectable or metastatic malignant melanoma has been transformed by the development of immune checkpoint inhibitors (e.g., Keytruda, Opdivo, Tecentriq) and…

The urticaria drug market is dominated by oral medications, including second-generation, nondrowsy antihistamines, prescribed for both chronic inducible and chronic spontaneous urticaria. However,…

The severe to very severe chronic obstructive pulmonary disease (COPD) drug market is becoming increasingly crowded as several LAMAs, LABA/ICSs, LABA/LAMAs, and, most recently, LABA/LAMA/ICSs…

The primary goal of hemophilia A treatment is to prevent bleeding. Hemophilia A patients are a heterogeneous cohort; the tendency to bleed is highly individual. Currently available treatments…

TNF-α inhibitors (AbbVie’s Humira, Amgen’s Enbrel, Janssen’s Remicade and Simponi, UCB’s Cimzia) are approved for the treatment of nonradiographic axial spondyloarthritis (nr-AxSpA) in…

Diabetic macular edema (DME) represents the second-largest ophthalmology market for intravitreal anti-VEGF therapies, including Roche / Novartis’s Lucentis and Regeneron / Bayer’s market-…

Obesity is a significant public health concern in the United States and Europe. Its chronic progression is associated with type 2 diabetes and adverse cardiovascular (CV) health. Following a series…

Although Ofev and Esbriet are welcome options in the treatment armamentarium for idiopathic pulmonary fibrosis (IPF), therapies that can further delay or reverse disease progression, preserve lung…

Although tumor necrosis factor-alpha (TNF-α) inhibitors remain the preferred treatments for psoriatic arthritis (PsA) following failure of conventional disease-modifying antirheumatic drugs (…

The approval of Dupixent has transformed the management of topical-refractory moderate to severe atopic dermatitis (AD), and the active, diverse AD pipeline is filled with compelling emerging…